Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing`s Sarcoma

Study:

Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma

Rationale:

Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Purpose:

This phase II trial is studying how well cytarabine works in treating young patients with recurrent or refractory Ewing`s sarcoma.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Sarcoma Drug: cytarabine Phase 2

Verified by Children`s Oncology Group August, 2013

Sponsored by: Children`s Oncology Group
Information provided by: Children`s Oncology Group
ClinicalTrials.gov identifier: NCT00470275

Study Type: Interventional

Study Design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Kimberly Stegmaier, MD., Study Chair
Holcombe E. Grier, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site